First detection of VEB-1 extended-spectrum β-lactamase-producing Escherichia coli clinical isolate in Japan
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.00523-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Junko Shindou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: beta-Lactamases, Escherichia coli, Escherichia coli Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development (AMED).
Abstract (Originalsprache)
The extended-spectrum β-lactamase (ESBL) gene, bla VEB-1 , was identified for the first time in an Escherichia coli clinical isolate, JARB-RN-0061, from blood cultures in a Japanese general hospital in 2021. The isolate exhibited high resistance to broad-spectrum cephalosporins, including ceftazidime (MIC >128 mg/L) and cefepime (MIC = 16 mg/L). bla VEB-1 was identified during whole-genome sequencing and characterization of the isolate. JARB-RN-0061 belonged to the B2-O2:K1:H7-ST95- fimH 41 lineage and was classified as presumptive extraintestinal pathogenic E. coli (ExPEC) and uropathogenic E. coli (UPEC). Moreover, the strain harbored multiple virulence genes on the chromosome. The Col156/IncFIB(AP001918)/IncFII(29)-type plasmid (114,216 bp), with clbB and tcpC genes involved in bacteremia, was unique to the fimH 41 subclone. The bla VEB-1 gene was located on a non-typeable and non-conjugative plasmid, pJARB-RN-0061_VEB-1 (17,093 bp). It was embedded in the class 1 integron In1883-like, with multidrug resistance gene cassettes for aacA4 , aadB , cmlA5 , qnrVC4 , and dfrA14 . Notably, comparative analysis of the complete sequence of plasmid pJARB-RN-0061_VEB-1 revealed that it was highly homologous to the bla VEB-1 -harboring plasmid, pMS2H7VEB-1 (100% coverage and 99.99% identity), except for the Tn3 family transposon (4,931 bp) and the plasmid pRHBSTW-00138_5 (97% coverage and 100% identity) harbored by Klebsiella quasipneumoniae subsp. similipneumoniae strains from hospital sewage in Japan and wastewater influent in the United Kingdom, respectively. The emergence of a human pathogenic E. coli clinical isolate with the bla VEB-1 -carrying plasmid in the B2-ST95 worldwide pandemic lineage, characterized by the virulence potential of ExPEC or UPEC but a low prevalence of antimicrobial resistance, would raise public health concerns. IMPORTANCE ESBLs are plasmid-mediated enzymes that confer resistance to clinically significant antimicrobial agents, such as broad-spectrum cephalosporins. Recently, the rapid spread of CTX-M-type ESBL-producing E. coli has become a global issue, including in Japan, where ESBL production in human pathogenic E. coli , such as the ExPEC and UPEC lineages, which typically harbor several virulence genes, is a severe public health concern. To date, VEB (Vietnamese extended-spectrum β-lactamase) producers have been found only in hospital wastewater and rivers in Japan. Thus, we describe the first detection of a very rare human-derived blaVEB-1 gene in the E. coli B2-ST95 pandemic clonal lineage that is highly associated with ExPEC and UPEC in a Japanese clinical setting. Furthermore, we characterized the genomic features of plasmids harboring the class 1 integron-borne blaVEB-1. Our findings highlight the significance of closely monitoring ESBL-producing E. coli isolates to prevent the potential dissemination of this resistance determinant in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
- Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
ORCID-Profile: Wataru Hayashi, Yo Sugawara, Motoyuki Sugai
Förderung
- Japan Agency for Medical Research and Development (AMED)
Zitieren
APA
Shindou, J., Hayashi, W., Kayama, S., Yu, L., Zuo, H., Sugawara, Y., & Sugai, M. (2024). First detection of VEB-1 extended-spectrum β-lactamase-producing Escherichia coli clinical isolate in Japan. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00523-24
Vancouver
Shindou J, Hayashi W, Kayama S, Yu L, Zuo H, Sugawara Y, et al. First detection of VEB-1 extended-spectrum β-lactamase-producing Escherichia coli clinical isolate in Japan. Microbiology Spectrum. 2024. doi:10.1128/spectrum.00523-24
BibTeX
@article{Shindou2024,
author = {Shindou, Junko and Hayashi, Wataru and Kayama, Shizuo and Yu, Liansheng and Zuo, Hui and Sugawara, Yo and Sugai, Motoyuki},
title = {First detection of VEB-1 extended-spectrum β-lactamase-producing Escherichia coli clinical isolate in Japan},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.00523-24}
}
EUVIMED